By Counterforce Health Team in Ultomiris (ravulizumab) —

How to Get Ultomiris (Ravulizumab) Approved by Blue Cross Blue Shield in New Jersey: Timeline, Appeals, and Documentation Guide

Answer Box: Getting Ultomiris Covered by Blue Cross Blue Shield in New Jersey

Ultomiris (ravulizumab) requires prior authorization from Blue Cross Blue Shield in New Jersey and is typically classified as non-preferred on most formularies. The fastest path to approval involves: 1) Gathering complete diagnostic documentation (lab results, vaccination records, prior therapy history), 2) Submitting a comprehensive prior authorization request through your provider's portal with medical necessity justification, and 3) If denied, filing an internal appeal within plan deadlines followed by New Jersey's Independent Health Care Appeals Program (IHCAP) external review if needed. Start today by contacting your prescribing physician to initiate the prior authorization process and ensure all required documentation is complete.

Table of Contents

What Affects Ultomiris Approval Timing

Several factors influence how quickly Blue Cross Blue Shield in New Jersey will approve Ultomiris (ravulizumab):

Benefit Type and Plan Structure

  • Commercial plans: Typically 3-7 business days for standard review
  • Medicare Advantage: May require additional CMS compliance checks
  • Medicaid managed care: Often has state-specific requirements that can extend timelines

Complexity of Clinical Criteria Ultomiris approval depends on meeting specific diagnostic and clinical requirements that vary by indication:

  • PNH (Paroxysmal Nocturnal Hemoglobinuria): Requires flow cytometry confirmation and LDH ≥1.5x upper normal limit
  • aHUS (Atypical Hemolytic Uremic Syndrome): Must exclude STEC-HUS and secondary causes
  • Generalized Myasthenia Gravis: Needs MG-ADL or QMG scores and MGFA class II-IV documentation
  • NMOSD: Requires positive anti-AQP4 antibody testing and ruled-out multiple sclerosis

Documentation Completeness The most significant factor affecting approval speed is having complete documentation from the start. Missing elements that commonly delay approval include:

  • Meningococcal vaccination records (required ≥2 weeks before treatment)
  • Prior therapy documentation and failure/intolerance records
  • Complete diagnostic lab results and imaging
  • Provider REMS program enrollment verification

Pre-Submission Preparation (0-2 Days)

Documentation Checklist

Essential Clinical Documents:

  • Complete medical history with diagnosis confirmation
  • Laboratory results specific to your condition:
    • PNH: Flow cytometry results, baseline LDH
    • aHUS: Complete metabolic panel, STEC testing
    • Myasthenia Gravis: MG-ADL/QMG scores, antibody testing
    • NMOSD: Anti-AQP4 antibody results, MRI reports
  • Vaccination records (meningococcal vaccine ≥2 weeks prior)
  • Prior medication trials and outcomes documentation
  • Current medication list and dosing requirements

Administrative Requirements:

  • Insurance card and member ID
  • Provider NPI and practice information
  • REMS program enrollment confirmation
  • Prior authorization form completion
Tip: Contact your specialty pharmacy or infusion center early in this process. They often have dedicated prior authorization specialists who can expedite the submission and follow up with your insurance plan.

Submission to Initial Review (1-5 Days)

How Blue Cross Blue Shield Reviews Ultomiris Requests

The initial review process typically follows this sequence:

  1. Administrative Check (Day 1): Verification of plan coverage, member eligibility, and form completeness
  2. Clinical Review (Days 2-4): Medical necessity assessment by clinical pharmacists or medical directors
  3. Specialty Review (Days 3-5): For complex cases, referral to specialists familiar with rare diseases

What Reviewers Check First:

  • Diagnosis confirmation with appropriate ICD-10 codes
  • FDA-approved indication alignment
  • Dosing within labeled parameters
  • Required safety monitoring (vaccination, lab values)
  • Prior authorization form accuracy and completeness

Horizon Blue Cross Blue Shield New Jersey Specifics As the largest insurer in New Jersey, Horizon BCBS classifies Ultomiris as non-preferred on their specialty formulary. This means:

  • Prior authorization is mandatory for all indications
  • Medical necessity documentation must justify why preferred alternatives aren't suitable
  • Requests may require step therapy completion or contraindication documentation

Additional Information Requests (1-7 Days)

If Blue Cross Blue Shield requests additional information, respond within 5 business days to avoid delays or automatic denials.

Common Information Requests:

  • Clarification of prior therapy failures or intolerances
  • Additional lab values or diagnostic imaging
  • Provider attestation letters
  • Vaccination documentation or prophylaxis plans

How to Respond Quickly:

  • Use the same submission method as your original request (portal, fax, mail)
  • Include your original prior authorization reference number
  • Provide a cover letter summarizing what additional information you're submitting
  • Follow up by phone within 24-48 hours to confirm receipt
Note: During the additional information period, your case is typically placed in a "hold queue." The review timeline restarts once complete information is received.

Decision Window and Outcomes

Typical Decision Timeline:

  • Standard Review: 5-7 business days from complete submission
  • Expedited Review: 2-3 business days (requires medical urgency documentation)

Reading Your Approval Letter:

  • Approved: Look for specific quantity limits, duration of approval, and renewal requirements
  • Approved with Conditions: May require specific dosing, monitoring, or provider qualifications
  • Denied: Will include specific denial reasons and appeal rights information

Partial Approvals: Sometimes Blue Cross Blue Shield may approve a lower dose or shorter duration than requested. This often occurs when:

  • Dosing exceeds typical protocols
  • Clinical documentation suggests starting with conservative dosing
  • Plan policies require step-up dosing protocols

If Denied: Appeal Process

Internal Appeals with Blue Cross Blue Shield

Level 1 Appeal (Peer-to-Peer Review):

  • Timeline: Request within 60 days of denial
  • Process: Your physician can request a direct conversation with the plan's medical director
  • Success rate: Often resolves coverage issues when clinical rationale is clearly communicated

Level 2 Appeal (Formal Written Appeal):

  • Timeline: 60 days from Level 1 denial
  • Documentation: Submit comprehensive medical necessity letter with supporting literature
  • Review period: 30 days for standard appeals, 72 hours for expedited appeals

Enhanced Medical Necessity Documentation

When appealing, your physician should include:

  • Detailed clinical rationale for Ultomiris specifically
  • Documentation of why preferred alternatives are unsuitable
  • Peer-reviewed literature supporting off-label use (if applicable)
  • Patient-specific factors requiring this particular therapy

Counterforce Health specializes in turning insurance denials into successful appeals by creating targeted, evidence-backed rebuttals that align with each plan's specific policies and requirements. Their platform helps identify the exact denial basis and drafts point-by-point responses using the right clinical evidence and procedural requirements.

Renewal Cycles and Maintenance

Initial Approval Periods:

  • PNH/aHUS: Typically 12 months
  • Myasthenia Gravis/NMOSD: Often 6 months initially, then annual renewals

Renewal Documentation Requirements:

  • Clinical response documentation (lab improvements, symptom scores)
  • Continued medical necessity attestation
  • Updated safety monitoring results
  • Any changes in dosing or administration

When to Submit Renewals: Begin the renewal process 30-45 days before your current approval expires to avoid treatment interruptions.

Timeline Visual and Milestones

Milestone Timeline Key Actions Expected Outcome
Pre-submission Days 0-2 Gather documentation, complete forms Ready for submission
Initial submission Day 1 Submit via provider portal/fax Confirmation received
Administrative review Days 1-2 Plan verifies eligibility, form completeness Proceeds to clinical review
Clinical review Days 3-7 Medical necessity assessment Approval, denial, or info request
Additional info period Days 1-7 Respond to plan requests Review resumes
Final decision Days 5-14 Plan renders final determination Approval letter or denial
Internal appeal Days 1-60 Submit appeal documentation Appeal decision
External review (IHCAP) Days 1-180 File with New Jersey IHCAP Binding external decision

Time-Saving Tips

Portal Usage Optimization:

  • Create accounts on both your provider's system and Blue Cross Blue Shield's provider portal
  • Upload all documents at once rather than piecemeal submissions
  • Use portal messaging for follow-up questions rather than phone calls

Bundled Evidence Approach:

  • Submit comprehensive documentation packages that anticipate likely questions
  • Include both required and supplementary evidence in initial submissions
  • Provide multiple forms of the same evidence when possible (lab reports, physician notes, imaging)

Direct Specialty Routing:

  • Request that your case be routed directly to the plan's rare disease or specialty pharmacy team
  • Identify the specific medical director who reviews complement inhibitor requests
  • Establish relationships with plan case managers for ongoing cases
From our advocates: We've seen cases where patients who submitted incomplete initial requests waited 3-4 weeks for approval, while those with comprehensive documentation received approval in 5-7 business days. The key difference was including vaccination records, detailed prior therapy documentation, and specific lab values in the initial submission rather than waiting for the plan to request them.

Common Denial Reasons and Solutions

Denial Reason Solution Strategy Required Documentation
Insufficient diagnosis documentation Submit complete diagnostic workup Flow cytometry (PNH), antibody testing, imaging reports
Missing vaccination records Provide vaccination documentation or prophylaxis plan Vaccination dates, lot numbers, or antibiotic prophylaxis protocol
Lack of prior therapy documentation Document previous treatments and outcomes Medication trial records, failure/intolerance documentation
Exceeding dosing parameters Justify higher doses with clinical rationale Weight-based calculations, clinical guidelines, specialist recommendations
Non-preferred drug status Request formulary exception Medical necessity letter, preferred alternative contraindications

New Jersey External Review Process

If Blue Cross Blue Shield upholds their denial after internal appeals, New Jersey offers robust external review rights through the Independent Health Care Appeals Program (IHCAP).

Key Features of New Jersey IHCAP:

  • No cost to patients - insurers pay all review fees
  • Independent medical review by specialty-appropriate physicians
  • Binding decisions on insurance companies
  • 180-day filing window from final internal denial

How to File an IHCAP Appeal:

  1. Complete Blue Cross Blue Shield's internal appeal process
  2. Submit external appeal request to Maximus (New Jersey's contracted review organization)
  3. Include all medical records, denial letters, and physician recommendations
  4. Wait for preliminary review and acceptance (5 business days)
  5. Provide any additional requested documentation (5 business days)
  6. Receive binding decision (typically within 45 days)

IHCAP Contact Information:

  • Phone: 1-888-393-1062
  • Online portal: njihcap.maximus.com
  • Consumer assistance: NJ Department of Banking and Insurance at 1-800-446-7467

The external review process has helped many New Jersey patients access specialty medications like Ultomiris when insurers initially denied coverage based on medical necessity determinations.

FAQ

How long does Blue Cross Blue Shield prior authorization take in New Jersey? Standard prior authorization typically takes 5-7 business days from complete submission. Expedited reviews (for urgent medical situations) can be completed in 2-3 business days.

What if Ultomiris is non-formulary on my Blue Cross Blue Shield plan? You can request a formulary exception by demonstrating medical necessity and documenting why preferred alternatives are unsuitable. This requires additional clinical justification but doesn't automatically result in denial.

Can I request an expedited appeal if my Ultomiris is denied? Yes, if you can demonstrate that a delay in treatment would cause serious harm to your health, you can request an expedited appeal. This must be documented by your physician and submitted with your appeal request.

Does step therapy apply if I've tried other treatments outside New Jersey? Previous treatments from other states typically count toward step therapy requirements, but you'll need complete documentation of those trials, including dates, doses, duration, and reasons for discontinuation.

What happens if I start Ultomiris before approval? Starting treatment before approval typically results in claim denials and personal financial responsibility. Always wait for written approval unless it's a true medical emergency with physician documentation.

How much does Ultomiris cost without insurance in New Jersey? Annual costs typically range from $474,000 to $569,000 for maintenance therapy, varying by weight and dosing requirements. Counterforce Health can help navigate coverage options and appeals to avoid these out-of-pocket expenses.

Can my doctor prescribe a different complement inhibitor while we appeal? Your physician may be able to prescribe Soliris (eculizumab) or other alternatives depending on your specific condition and your plan's formulary. This can serve as bridge therapy while appealing for Ultomiris coverage.

What if my Blue Cross Blue Shield plan changes its Ultomiris policy mid-year? Plans cannot typically change coverage policies mid-year for existing patients without proper notification periods. If you're currently approved, your coverage should continue through your approval period even if policies change.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Insurance coverage policies change frequently, and individual circumstances vary. Always consult with your healthcare provider and insurance plan for the most current information specific to your situation. For questions about New Jersey insurance regulations, contact the NJ Department of Banking and Insurance at 1-800-446-7467.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.